source
- STAT+: MAHA goes corporateHealth care companies dominate the MAHA Summit, and a look at Trump's watered down effort to lower Medicare drug prices.STAT · 20d ago↗ source
- Eli Lilly’s Zepbound plus amylin candidate shows 23% weight loss in phase 2 trial, but many patients stopped treatmentEli Lilly tested a combination of its GLP‑1 obesity drug Zepbound with the amylin‑targeting candidate eloralintide in a mid‑stage study of people with obesity and type 2 diabetes. After 48 weeks,…